Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
Impact of early-onset colorectal cancer on utilization of chemotherapy and outcomes in patients with stage II disease. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers ...
Announces majority investment in NGS bioinformatics solution provider Ridom GmbH New NGS microbiology solutions for hygiene testing and epidemiological studies HAI (Hospital-Acquired Infections) ...
Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in Muenster, Germany. Ridom´s NGS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results